Biofourmis lands $100M in Series C funding round

The Company will use funding to bring new digital therapeutic solutions to market

Stethoscope on a computer keyboard

Biofourmis, which combines AI-based data analytics with medical-grade biosensors to provide personalized, predictive care, announced it’s completed a $100 million Series C financing round. SoftBank Vision Fund 2 led the funding round, with existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI participating too.

Biofourmis closed its $35 million Series B funding round just a year ago and has since increased its revenue significantly through new partnerships with seven pharmaceutical companies and 10 health systems worldwide, including Novartis, AstraZeneca and Mayo Clinic. 

Biofourmis says it will use the funding to develop, validate and bring new digital therapeutic solutions for cardiology, respiratory, oncology and pain treatments to the market. The company also plans to focus on the U.S. and Asian markets, including Asia Pacific, China and Japan.

Biofourmis CEO Kuldeep Singh Rajput said, "Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy.”

“With this new funding, we will accelerate our global expansion, advance our digital therapeutics pipeline, develop additional care pathways and drive deeper integration with our health system, hospital, pharmaceutical and clinical research clients and partners," Kuldeep added.

Biofourmis also announced an alignment of its internal operations. The new business structure will include two verticals: Biofourmis Therapeutics, which will focus on developing clinically validated software-based therapeutics and Biofourmis Health, which will leverage the company's AI-based remote monitoring system to lower health care costs and improve patient outcomes.

"In the last seven months, healthcare has fast-forwarded by at least five years," Rajput said. "Despite a challenging global economic environment due to the COVID-19 pandemic, we expect that our latest funding round will accelerate Biofourmis' plans to rapidly scale to support more healthcare provider, pharmaceutical and health plan clients across the world. We will continue to drive an evolution toward a more personalized and predictive remote method of care delivery that patients prefer and that enables better outcomes."

Featured Resources

Four cyber security essentials that your board of directors wants to know

The insights to help you deliver what they need

Download now

Data: A resource much too valuable to leave unprotected

Protect your data to protect your company

Download now

Improving cyber security for remote working

13 recommendations for security from any location

Download now

Why CEOS should care about the move to SAP S/4HANA

And how they can accelerate business value

Download now

Recommended

AI-based reminiscence pilot aims to stimulate recall in memory care patients
telepresence

AI-based reminiscence pilot aims to stimulate recall in memory care patients

19 Nov 2020
Outcomes4Me raises $4.7M for its AI-powered breast cancer care app
communications

Outcomes4Me raises $4.7M for its AI-powered breast cancer care app

18 Nov 2020
VectorCare expands offerings to meet surging mobile health care demands
software as a service (SaaS)

VectorCare expands offerings to meet surging mobile health care demands

15 Oct 2020
Google and Amwell team up to boost telehealth services
Cloud

Google and Amwell team up to boost telehealth services

25 Aug 2020

Most Popular

macOS Big Sur is bricking some older MacBooks
operating systems

macOS Big Sur is bricking some older MacBooks

16 Nov 2020
46 million Animal Jam accounts leaked after comms software breach
Security

46 million Animal Jam accounts leaked after comms software breach

13 Nov 2020
How computing has revolutionised Formula 1
Sponsored

How computing has revolutionised Formula 1

11 Nov 2020